Literature DB >> 15996751

A rating scale for neuroleptic malignant syndrome.

Perminder S Sachdev1.   

Abstract

The development of a rating scale for neuroleptic malignant syndrome (NMS) is described. The clinical and laboratory features of NMS were categorised into six domains after a thorough literature review and examination of patients. The reliability of this scale was established on 25 NMS patients and 50 control subjects based on chart reviews. A factor analysis supported a six-factor solution. The validity of the scale was indicated by the relationship of the severity rating to duration of illness and outcome. The inter-rater reliability of the scale was established prospectively in 10 subjects. The scale offers a measure of severity of NMS in the clinical setting so as to support the clinical diagnosis, monitor patients and determine their progress. The scale may be applicable not only to NMS or suspected NMS but also to NMS-like syndromes such as lethal catatonia.

Entities:  

Mesh:

Year:  2005        PMID: 15996751     DOI: 10.1016/j.psychres.2005.05.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  Neuroleptic malignant syndrome associated with quetiapine and venlafaxine use: a case report and discussion.

Authors:  Gary Woods; Catherine Taggart; Robert Boggs; Ian Cadden
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

2.  Schizophrenia and anaesthesia.

Authors:  Liew Sat Lin Constance; Meryl Grace Lansing; Foo Kiang Khor; Rajesh Kumar Muniandy
Journal:  BMJ Case Rep       Date:  2017-11-23

Review 3.  Catatonia: diagnosis, classification, and treatment.

Authors:  Andrew Francis
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 4.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Elevated creatine kinase does not necessarily correspond temporally with onset of muscle rigidity in neuroleptic malignant syndrome: a report of two cases.

Authors:  Koichi Nisijima
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-13       Impact factor: 2.570

6.  A rare case of neuroleptic malignant syndrome without elevated serum creatine kinase.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-24       Impact factor: 2.570

7.  [Association of atypical neuroleptics with anticonvulsants and malignant syndrome. Report of 2 cases].

Authors:  Fadoua Oueriagli Nabih; Abdeslam Benali; Imane Adali; Fatiha Manoudi; Fatima Asri
Journal:  Pan Afr Med J       Date:  2014-07-16

Review 8.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

9.  Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-18       Impact factor: 2.570

10.  Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register.

Authors:  Chin-Kuo Chang; Simon Harrison; William Lee; David Taylor; Robert Stewart
Journal:  Ther Adv Psychopharmacol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.